Based on recent studies suggesting that MYC upregulates immune checkpoint pathways such as programmed death-ligand 1 (PD-L1) [42], immunotherapy can be added to CD5+ DLBCL patients overexpressing MYC. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.